Thromboembolic Events in Severe COVID-19 Patients
COVICLOT
Incidence of Thromboembolic Events and Prognosis of COVID-19 Patients Hospitalized in Intensive Care Units in France
1 other identifier
observational
300
1 country
1
Brief Summary
The main objective of this study is to describe the incidence of thromboembolic events in a population of patients hospitalized in intensive care units in France for severe COVID-19. The secondary objective of this study is to describe the evolution of hemostasis parameters during the first two weeks of intensive care hospitalization and to evaluate the influence of different anticoagulation regimens on these parameters and on the incidence of thromboembolic events
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Apr 2020
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 29, 2020
CompletedFirst Submitted
Initial submission to the registry
May 25, 2020
CompletedFirst Posted
Study publicly available on registry
May 28, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
April 1, 2021
CompletedMay 29, 2020
May 1, 2020
11 months
May 25, 2020
May 27, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Analysis of incidence of thromboembolic events in patients with Sars-CoV-2
1 month
Eligibility Criteria
Patients with a confirmed infection with the Sars-CoV-2 virus
You may qualify if:
- Confirmed infection with the Sars-CoV-2 virus (RT-PCR)
- Hospitalization in Intensive Care Unit
- Age over 18 years Old
You may not qualify if:
- Refusal of the patient to participate in data collection
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Service d'Anesthésie-Réanimation - Nouvel Hôpital Civil
Strasbourg, 67091, France
Related Publications (1)
Tacquard C, Mansour A, Godon A, Godet J, Poissy J, Garrigue D, Kipnis E, Rym Hamada S, Mertes PM, Steib A, Ulliel-Roche M, Bouhemad B, Nguyen M, Reizine F, Gouin-Thibault I, Besse MC, Collercandy N, Mankikian S, Levy JH, Gruel Y, Albaladejo P, Susen S, Godier A; French Working Group on Perioperative Hemostasis. Impact of High-Dose Prophylactic Anticoagulation in Critically Ill Patients With COVID-19 Pneumonia. Chest. 2021 Jun;159(6):2417-2427. doi: 10.1016/j.chest.2021.01.017. Epub 2021 Jan 16.
PMID: 33465342DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- OTHER
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 25, 2020
First Posted
May 28, 2020
Study Start
April 29, 2020
Primary Completion
April 1, 2021
Study Completion
April 1, 2021
Last Updated
May 29, 2020
Record last verified: 2020-05